Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by MediWound Ltd.
< Previous
1
2
Next >
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
September 29, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
September 25, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
September 02, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
August 20, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 14, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
August 13, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Report Second Quarter 2025 Financial Results
August 04, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 21, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
May 13, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Report First Quarter 2025 Financial Results
May 05, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
April 28, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 19, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results
March 03, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
February 25, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Present at the 45th Annual TD Cowen Health Care Conference
February 24, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
February 12, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 04, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
December 17, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
November 26, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Report Third Quarter 2024 Financial Results
November 12, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
October 10, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
October 08, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
August 15, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
August 14, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
August 05, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Report Second Quarter 2024 Financial Results
August 02, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
July 29, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
July 16, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces $25 Million Strategic Private Placement Financing
July 15, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today